NCT04829006 is a NA clinical trial of Understand Me For Life in Parkinson Disease, sponsored by Long Island University.

Who is sponsoring NCT04829006?

NCT04829006 is sponsored by Long Island University.

What drugs are being tested in NCT04829006?

Interventions in NCT04829006: Understand Me For Life.

What condition does NCT04829006 study?

NCT04829006 studies Parkinson Disease.

Is NCT04829006 still recruiting?

NCT04829006 is currently completed. Last updated 12 April 2022.

Last reviewed 2022-04-12 · How we verify

NCT04829006

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intelligibility Assessment for Parkinson's Disease

Completed NA Last updated 12 April 2022

What this trial tests

NA trial testing Understand Me For Life in Parkinson Disease in 70 participants. Completed in 4 April 2022.

Timeline

1 April 2021

Primary endpoint
31 March 2022

4 April 2022

Quick facts

Lead sponsor	Long Island University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	70
Start date	1 April 2021
Primary completion	31 March 2022
Estimated completion	4 April 2022
Sites	1 location across United States

Drugs / interventions tested

Understand Me For Life

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Long Island University

Who can join

Adults 30 to 85, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim at testing the efficacy of an app to measure sentence intelligibility in noise in speakers with Parkinson's disease and in healthy controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Long Island University trials

Trials by the same sponsor.

NCT05265741 — Gestational Diabetes Mellitus (GDM) in Pregnant Women · unknown
NCT03813329 — Effects of Novel Sodium Bicarbonate Ingestion of Buffering Capacity · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04829006 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Long Island University
Last refreshed: 12 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04829006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing